person · Reporting owner

Walbert Timothy P

Disclosed activity across 14 companies

Tapewire entity: 25937
SEC CIK: 0001349376

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Assertio Holdings, Inc.ASRT · Entity 37706	Director	May 20, 2020	May 23, 2020
Aurinia Pharmaceuticals Inc.AUPH · Entity 4463	Director	May 18, 2022	May 20, 2022
BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404	Director	June 02, 2026	June 04, 2026
Century Therapeutics, Inc.IPSC · Entity 5739	Director	June 12, 2025	June 16, 2025
EXICURE, INC.XCUR · Entity 8068	Director	June 02, 2021	June 04, 2021
Kardigan, Inc.KARD · Entity 4569	Director	June 17, 2026	June 22, 2026
Latigo Biotherapeutics, Inc.LTGO · Entity 4709	Director	August 06, 2026	August 07, 2026
Mirum Pharmaceuticals, Inc.MIRM · Entity 2416	Director	June 15, 2026	June 18, 2026
Odyssey Therapeutics, Inc.ODTX · Entity 4850	Director	May 07, 2026	May 12, 2026
Sagimet Biosciences Inc.SGMT · Entity 5273	Director	June 09, 2025	June 10, 2025
XOMA Royalty CorpXOMA · Entity 30207	Director	February 10, 2017	May 22, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Assertio Holdings, Inc.

Report date May 20, 2020 · Filed May 23, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	49,143	Reported balance After 2020-05-20 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2020-05-20 · Grant · Acquired 49,143 · Balance 49,143 F1: Common stock of Assertio Holdings, Inc. ("Issuer") acquired at the effective time ("Effective Time") of the transactions contemplated in the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Zyla Life Sciences ("Zyla") and the other parties thereto. Pursuant to the Merger Agreement, each share of Zyla common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive, and became exchangeable for 2.5 shares of Issuer common stock. Issuer common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time. F2: Additionally, all outstanding time-based restricted stock units of Zyla were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Issuer common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Zyla common stock covered by such restricted stock unit. F3: Totals exclude shares withheld by the Issuer for applicable tax withholdings.
Common StockSEC Table I · non-derivative	Direct	211,111	Reported balance After 2020-05-20 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2020-05-20 · Grant · Acquired 211,111 · Balance 211,111 F4: One-third of these restricted stock units are scheduled to vest on each of May 20, 2021, 2022 and 2023, assuming continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Common stock of Assertio Holdings, Inc. ("Issuer") acquired at the effective time ("Effective Time") of the transactions contemplated in the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Zyla Life Sciences ("Zyla") and the other parties thereto. Pursuant to the Merger Agreement, each share of Zyla common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive, and became exchangeable for 2.5 shares of Issuer common stock. Issuer common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time.

F2: Additionally, all outstanding time-based restricted stock units of Zyla were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Issuer common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Zyla common stock covered by such restricted stock unit.

F3: Totals exclude shares withheld by the Issuer for applicable tax withholdings.

F4: One-third of these restricted stock units are scheduled to vest on each of May 20, 2021, 2022 and 2023, assuming continued service through the applicable vesting date.

Aurinia Pharmaceuticals Inc.

Report date May 18, 2022 · Filed May 20, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	8,733	Reported balance After 2022-05-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-05-18 · Grant · Acquired 8,733 · Balance 8,733 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuers common stock. The RSUs will vest and be delivered to the Reporting Person one year from date of grant.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.45 · Expires 2032-05-18	Direct	14,612	Reported balance After 2022-05-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-05-18 · Grant · Acquired 14,612 · Balance 14,612 F2: The option vests in twelve equal monthly installments commencing on June 18, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuers common stock. The RSUs will vest and be delivered to the Reporting Person one year from date of grant.

F2: The option vests in twelve equal monthly installments commencing on June 18, 2022.

BIOMARIN PHARMACEUTICAL INC

Report date June 02, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	17,270	Reported balance After 2026-06-02 transaction · row 1 1 source row Row 1 · 2026-06-02 · Grant · Acquired 7,490 · Balance 17,270 F1: Restricted stock units granted on June 2, 2026. Price not applicable.
Common StockSEC Table I · non-derivative	IndirectShares held by Prairie Capital Ventures LLC	416	Reported balance Holding disclosure · report date 2026-06-02 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 416

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units granted on June 2, 2026. Price not applicable.

Century Therapeutics, Inc.

Report date June 12, 2025 · Filed June 16, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2035-06-12	Direct	44,000	Reported balance After 2025-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-06-12 · Grant · Acquired 44,000 · Balance 44,000 F1: The option vests on the earlier of (a) June 12, 2026, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests on the earlier of (a) June 12, 2026, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

EXICURE, INC.

Report date June 02, 2021 · Filed June 04, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2031-06-01	Direct	50,000	Reported balance After 2021-06-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-06-02 · Grant · Acquired 50,000 · Balance 50,000 F1: The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 2, 2021, provided the Reporting Person remains in continuous service on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will vest as to 1/12th of the underlying shares monthly from the vesting commencement date of June 2, 2021, provided the Reporting Person remains in continuous service on each vesting date.

Kardigan, Inc.

Report date June 17, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	20,706	Reported balance After 2026-06-17 transaction · row 1 1 source row Row 1 · 2026-06-17 · Grant · Acquired 20,706 · Balance 20,706 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-06-16	Direct	57,573	Reported balance After 2026-06-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-17 · Grant · Acquired 57,573 · Balance 57,573 F2: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments commencing from June 17, 2026, subject to the Reporting Person's continued service on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date.

F2: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments commencing from June 17, 2026, subject to the Reporting Person's continued service on each such vesting date.

Latigo Biotherapeutics, Inc.

Report date August 06, 2026 · Filed August 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.19 · Expires 2034-10-29	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-08-06 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: The shares subject to this option shall vest in 48 equal monthly installments after October 30, 2024. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.53 · Expires 2035-02-04	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-08-06 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F2: One-fourth of the total shares subject to this option shall vest one year after January 28, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.53 · Expires 2035-04-07	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-08-06 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F2: One-fourth of the total shares subject to this option shall vest one year after January 28, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option shall vest in 48 equal monthly installments after October 30, 2024. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

F2: One-fourth of the total shares subject to this option shall vest one year after January 28, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

Mirum Pharmaceuticals, Inc.

Report date June 15, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $101.00 · Expires 2036-06-14	Direct	3,772	Reported balance After 2026-06-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-15 · Grant · Acquired 3,772 · Balance 3,772 F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	1,980	Reported balance After 2026-06-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-15 · Grant · Acquired 1,980 · Balance 1,980 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.

Filing footnotes · ownership attribution and instrument terms

F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.

F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.

Odyssey Therapeutics, Inc.

Report date May 07, 2026 · Filed May 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06	Direct	27,393	Reported balance After 2026-05-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-07 · Grant · Acquired 27,393 · Balance 27,393 F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.

Sagimet Biosciences Inc.

Report date June 09, 2025 · Filed June 10, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.33 · Expires 2035-06-08	Direct	32,250	Reported balance After 2025-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-06-09 · Grant · Acquired 32,250 · Balance 32,250 F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date.

XOMA Royalty Corp

Report date February 10, 2017 · Filed May 22, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Non-Qualified Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.03 · Expires 2027-02-10	Direct	8,000	Reported balance After 2017-02-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-02-10 · Grant · Acquired 8,000 · Balance 8,000 F1: This option was approved by the Board of Directors of the Issuer on February 10, 2017, subject to approval by the Issuer's stockholders, at the 2017 Annual Meeting of Stockholders, of an amendment of the Issuer's 2010 Long Term Incentive and Stock Award Plan (the "Plan"), including an increase in the number of shares reserved for issuance under the Plan (the "Amendment"). The Stockholders of the Issuer approved the Amendment on May 18, 2017. F2: Shares subject to this option shall vest in equal monthly installments over three years from the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: This option was approved by the Board of Directors of the Issuer on February 10, 2017, subject to approval by the Issuer's stockholders, at the 2017 Annual Meeting of Stockholders, of an amendment of the Issuer's 2010 Long Term Incentive and Stock Award Plan (the "Plan"), including an increase in the number of shares reserved for issuance under the Plan (the "Amendment"). The Stockholders of the Issuer approved the Amendment on May 18, 2017.

F2: Shares subject to this option shall vest in equal monthly installments over three years from the grant date.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Horizon Therapeutics Public Ltd Co

Report date October 06, 2023 · Filed October 06, 2023

Section 16 reporting ended · disclosed 2023-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Reported balance After 2023-10-06 transaction · row 1 1 source row Row 1 · 2023-10-06 · Disposition to issuer · Disposed 616,772 · Balance 0 F1: Includes 279 Ordinary Shares (as defined in footnote 2 of this Form 4) acquired by the reporting person on June 1, 2023 pursuant to an employee stock purchase program. F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
Ordinary SharesSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2023-10-06 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2023-10-06 · Disposition to issuer · Disposed 107,739 · Balance 0 F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). F3: The Ordinary Shares are held by the Timothy P. Walbert 2021 Gift Trust, of which the Reporting Person's spouse is the Trustee and beneficiary.
Ordinary SharesSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2023-10-06 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2023-10-06 · Disposition to issuer · Disposed 100,300 · Balance 0 F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). F4: The Ordinary Shares are held by the Keli B. Walbert 2021 Gift Trust, of which the Reporting Person is the Trustee. The beneficiaries of the Trust include the Reporting Person and his descendants.
Ordinary SharesSEC Table I · non-derivative	IndirectBy Spouse	Reported balance After 2023-10-06 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2023-10-06 · Disposition to issuer · Disposed 49,935 · Balance 0 F1: Includes 279 Ordinary Shares (as defined in footnote 2 of this Form 4) acquired by the reporting person on June 1, 2023 pursuant to an employee stock purchase program. F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.14 · Expires 2025-03-22	Direct	Reported balance After 2023-10-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-10-06 · Disposition to issuer · Disposed 742,565 · Balance 0 F6: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F5: The Option (as defined in footnote 6 to this Form 4) is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.53 · Expires 2025-03-22	Direct	Reported balance After 2023-10-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-10-06 · Disposition to issuer · Disposed 1,650,000 · Balance 0 F6: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F5: The Option (as defined in footnote 6 to this Form 4) is fully vested.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-10-06 · Disposition to issuer · Disposed 34,929 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F9: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 14 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F8: The Ordinary Shares subject to the RSUs vest on January 5, 2024.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-10-06 · Disposition to issuer · Disposed 49,198 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F9: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 14 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F10: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2022.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-10-06 · Disposition to issuer · Disposed 71,290 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F9: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 14 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F11: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2023.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-10-06 · Disposition to issuer · Disposed 45,843 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F12: The Ordinary Shares subject to the PSUs (as defined in footnote 13 to this Form 4) vest on January 5, 2024.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2023-10-06 · Disposition to issuer · Disposed 17,448 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F12: The Ordinary Shares subject to the PSUs (as defined in footnote 13 to this Form 4) vest on January 5, 2024.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2023-10-06 · Disposition to issuer · Disposed 104,786 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F12: The Ordinary Shares subject to the PSUs (as defined in footnote 13 to this Form 4) vest on January 5, 2024.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2023-10-06 · Disposition to issuer · Disposed 14,759 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F14: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2024 and the remaining shares vest on January 5, 2025.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2023-10-06 · Disposition to issuer · Disposed 44,278 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F15: The Ordinary Shares subject to the PSUs vest on January 5, 2025.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2023-10-06 · Disposition to issuer · Disposed 73,798 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F15: The Ordinary Shares subject to the PSUs vest on January 5, 2025.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2023-10-06 · Disposition to issuer · Disposed 35,645 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F16: The Ordinary Shares subject to the PSUs vest on January 5, 2026.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2023-10-06 · Disposition to issuer · Disposed 17,823 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F17: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2023-10-06 · Disposition to issuer · Disposed 17,823 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F17: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026.
Restricted Stock UnitsSEC Table II · derivative / convertible security	IndirectBy Spouse	Reported balance After 2023-10-06 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2023-10-06 · Disposition to issuer · Disposed 4,657 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F9: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 14 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F12: The Ordinary Shares subject to the PSUs (as defined in footnote 13 to this Form 4) vest on January 5, 2024.
Restricted Stock UnitsSEC Table II · derivative / convertible security	IndirectBy Spouse	Reported balance After 2023-10-06 transaction · row 20 Instrument identity requires review; Table II rows are not merged. 1 source row Row 20 · 2023-10-06 · Disposition to issuer · Disposed 14,283 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F9: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 14 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F10: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2022.
Restricted Stock UnitsSEC Table II · derivative / convertible security	IndirectBy Spouse	Reported balance After 2023-10-06 transaction · row 21 Instrument identity requires review; Table II rows are not merged. 1 source row Row 21 · 2023-10-06 · Disposition to issuer · Disposed 20,697 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F9: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 14 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F11: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2023.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	IndirectBy Spouse	Reported balance After 2023-10-06 transaction · row 22 Instrument identity requires review; Table II rows are not merged. 1 source row Row 22 · 2023-10-06 · Disposition to issuer · Disposed 21,426 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F15: The Ordinary Shares subject to the PSUs vest on January 5, 2025.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	IndirectBy Spouse	Reported balance After 2023-10-06 transaction · row 23 Instrument identity requires review; Table II rows are not merged. 1 source row Row 23 · 2023-10-06 · Disposition to issuer · Disposed 12,854 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F15: The Ordinary Shares subject to the PSUs vest on January 5, 2025.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	IndirectBy Spouse	Reported balance After 2023-10-06 transaction · row 24 Instrument identity requires review; Table II rows are not merged. 1 source row Row 24 · 2023-10-06 · Disposition to issuer · Disposed 4,285 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F14: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2024 and the remaining shares vest on January 5, 2025.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	IndirectBy Spouse	Reported balance After 2023-10-06 transaction · row 25 Instrument identity requires review; Table II rows are not merged. 1 source row Row 25 · 2023-10-06 · Disposition to issuer · Disposed 10,349 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F16: The Ordinary Shares subject to the PSUs vest on January 5, 2026.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	IndirectBy Spouse	Reported balance After 2023-10-06 transaction · row 26 Instrument identity requires review; Table II rows are not merged. 1 source row Row 26 · 2023-10-06 · Disposition to issuer · Disposed 5,174 · Balance 0 F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F17: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	IndirectBy Spouse	Reported balance After 2023-10-06 transaction · row 27 Instrument identity requires review; Table II rows are not merged. 1 source row Row 27 · 2023-10-06 · Disposition to issuer · Disposed 5,174 · Balance 0 F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F17: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 279 Ordinary Shares (as defined in footnote 2 of this Form 4) acquired by the reporting person on June 1, 2023 pursuant to an employee stock purchase program.

F2: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").

F3: The Ordinary Shares are held by the Timothy P. Walbert 2021 Gift Trust, of which the Reporting Person's spouse is the Trustee and beneficiary.

F4: The Ordinary Shares are held by the Keli B. Walbert 2021 Gift Trust, of which the Reporting Person is the Trustee. The beneficiaries of the Trust include the Reporting Person and his descendants.

F5: The Option (as defined in footnote 6 to this Form 4) is fully vested.

F6: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option.

F7: Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer.

F8: The Ordinary Shares subject to the RSUs vest on January 5, 2024.

F9: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 14 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme.

F10: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2022.

F11: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2023.

F12: The Ordinary Shares subject to the PSUs (as defined in footnote 13 to this Form 4) vest on January 5, 2024.

F13: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration.

F14: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2024 and the remaining shares vest on January 5, 2025.

F15: The Ordinary Shares subject to the PSUs vest on January 5, 2025.

F16: The Ordinary Shares subject to the PSUs vest on January 5, 2026.

F17: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026.

Sucampo Pharmaceuticals, Inc.

Report date February 13, 2018 · Filed February 13, 2018

Section 16 reporting ended · disclosed 2018-02-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, Class ASEC Table I · non-derivative	Direct	0	Reported balance After 2018-02-13 transaction · row 1 1 source row Row 1 · 2018-02-13 · Disposition to issuer · Disposed 5,130 · Balance 0 F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of restricted stock units that were accelerated as a result of the Merger Agreement.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.30 · Expires 2027-06-01	Direct	0	Reported balance After 2018-02-13 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-02-13 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of restricted stock units that were accelerated as a result of the Merger Agreement.

F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.

Zyla Life Sciences

Report date May 20, 2020 · Filed May 21, 2020

Section 16 reporting ended · disclosed 2020-05-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2020-05-20 transaction · row 1 1 source row Row 1 · 2020-05-20 · Disposition to issuer · Disposed 26,953 · Balance 0 F1: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time. F2: Includes unvested time-based restricted stock units representing a contingent right to receive 26, 953 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit.

Filing footnotes · ownership attribution and instrument terms

F1: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time.

F2: Includes unvested time-based restricted stock units representing a contingent right to receive 26, 953 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 22, 2021 Filed Jan 22, 2021 20:59 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	7,452	$76.25	$568,224.69	Disclosure SEC source: 0001209191-21-004992 · doc4.xml · nonDerivative · entry 3 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950,430 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.79 to $76.78 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 21, 2021 Filed Jan 22, 2021 20:59 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionPerformance Restricted Stock Units (PSUs) · Derivative	2,575	$0.00	$0.00	Disclosure SEC source: 0001209191-21-004992 · doc4.xml · derivative · entry 8 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 Underlying: Ordinary Shares · 2,575 shares Expires 2021-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
January 21, 2021 Filed Jan 22, 2021 20:59 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionPerformance Restricted Stock Units (PSUs) · Derivative	20,330	$0.00	$0.00	Disclosure SEC source: 0001209191-21-004992 · doc4.xml · derivative · entry 7 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,336 Underlying: Ordinary Shares · 20,330 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: The shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. F5 · derivative.expiration_date: The shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. Read SEC document
January 21, 2021 Filed Jan 22, 2021 20:59 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Tax withholdingOrdinary Shares	755	$77.43	$58,459.65	Disclosure SEC source: 0001209191-21-004992 · doc4.xml · nonDerivative · entry 6 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 13,808 Read SEC document
January 21, 2021 Filed Jan 22, 2021 20:59 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionOrdinary Shares	2,575	$0.00	$0.00	Disclosure SEC source: 0001209191-21-004992 · doc4.xml · nonDerivative · entry 5 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 14,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 21, 2021 Filed Jan 22, 2021 20:59 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Tax withholdingOrdinary Shares	9,007	$77.43	$697,412.01	Disclosure SEC source: 0001209191-21-004992 · doc4.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 957,882 Read SEC document
January 21, 2021 Filed Jan 22, 2021 20:59 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionOrdinary Shares	20,330	$0.00	$0.00	Disclosure SEC source: 0001209191-21-004992 · doc4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 966,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 15, 2021 Filed Jan 15, 2021 17:43 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	2,299	$79.10	$181,850.90	Disclosure SEC source: 0001209191-21-003867 · doc4.xml · nonDerivative · entry 3 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 946,559 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2020. Read SEC document
January 15, 2021 Filed Jan 15, 2021 17:43 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	127,504	$78.26	$9,978,756.30	Disclosure SEC source: 0001209191-21-003867 · doc4.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 948,858 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2020. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.855 to $78.725 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 15, 2021 Filed Jan 15, 2021 17:43 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	81,401	$77.26	$6,289,285.46	Disclosure SEC source: 0001209191-21-003867 · doc4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,076,362 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.85 to $77.83 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 05, 2021 Filed Jan 6, 2021 21:03 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units (RSU) · Derivative	3,386	$0.00	$0.00	Disclosure SEC source: 0001209191-21-002408 · doc4.xml · derivative · entry 11 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 6,773 Underlying: Ordinary Shares · 3,386 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F3 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document
January 05, 2021 Filed Jan 6, 2021 21:03 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units (RSU) · Derivative	58,055	$0.00	$0.00	Disclosure SEC source: 0001209191-21-002408 · doc4.xml · derivative · entry 10 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,110 Underlying: Ordinary Shares · 58,055 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F3 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document
January 05, 2021 Filed Jan 6, 2021 21:03 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units (RSU) · Derivative	152,967	$0.00	$0.00	Disclosure SEC source: 0001209191-21-002408 · doc4.xml · derivative · entry 9 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 152,967 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. F5 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. Read SEC document
January 05, 2021 Filed Jan 6, 2021 21:03 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units (RSU) · Derivative	58,035	$0.00	$0.00	Disclosure SEC source: 0001209191-21-002408 · doc4.xml · derivative · entry 8 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,035 Underlying: Ordinary Shares · 58,035 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. F4 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. Read SEC document
January 05, 2021 Filed Jan 6, 2021 21:03 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Tax withholdingOrdinary Shares	1,597	$73.28	$117,028.16	Disclosure SEC source: 0001209191-21-002408 · doc4.xml · nonDerivative · entry 5 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 11,988 Read SEC document
January 05, 2021 Filed Jan 6, 2021 21:03 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionOrdinary Shares	3,386	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-002408 · doc4.xml · nonDerivative · entry 4 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 13,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
January 05, 2021 Filed Jan 6, 2021 21:03 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Tax withholdingOrdinary Shares	337,380	$73.28	$24,723,206.40	Disclosure SEC source: 0001209191-21-002408 · doc4.xml · nonDerivative · entry 3 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,157,763 Read SEC document
January 05, 2021 Filed Jan 6, 2021 21:03 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantOrdinary Shares	492,294	$0.00	$0.00	Disclosure SEC source: 0001209191-21-002408 · doc4.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,495,143 F2 · kind: On January 5, 2018 and January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 5, 2021, the PSUs vested as to the number of shares reported above. Read SEC document
January 05, 2021 Filed Jan 6, 2021 21:03 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionOrdinary Shares	269,057	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-002408 · doc4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,002,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
January 04, 2021 Filed Jan 6, 2021 21:03 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantRestricted Stock Units (RSU) · Derivative	13,971	$0.00	$0.00	Disclosure SEC source: 0001209191-21-002408 · doc4.xml · derivative · entry 7 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 13,971 Underlying: Ordinary Shares · 13,971 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F3 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document
January 04, 2021 Filed Jan 6, 2021 21:03 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantRestricted Stock Units (RSU) · Derivative	104,785	$0.00	$0.00	Disclosure SEC source: 0001209191-21-002408 · doc4.xml · derivative · entry 6 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,785 Underlying: Ordinary Shares · 104,785 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F3 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document
August 06, 2020 Filed Aug 7, 2020 17:42 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	1,300	$75.75	$98,470.19	Disclosure SEC source: 0001209191-20-045701 · doc4.xml · nonDerivative · entry 7 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 733,792 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 17, 2020. F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.6325 to $75.7750 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 06, 2020 Filed Aug 7, 2020 17:42 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	22,120	$75.19	$1,663,123.17	Disclosure SEC source: 0001209191-20-045701 · doc4.xml · nonDerivative · entry 6 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 735,092 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 17, 2020. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.60 to $75.565 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 06, 2020 Filed Aug 7, 2020 17:42 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	14,718	$73.86	$1,087,139.18	Disclosure SEC source: 0001209191-20-045701 · doc4.xml · nonDerivative · entry 5 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 757,212 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 17, 2020. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.535 to $74.345 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 06, 2020 Filed Aug 7, 2020 17:42 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	18,263	$72.75	$1,328,720.91	Disclosure SEC source: 0001209191-20-045701 · doc4.xml · nonDerivative · entry 4 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771,930 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 17, 2020. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.30 to $73.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 06, 2020 Filed Aug 7, 2020 17:42 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	11,262	$71.57	$805,990.93	Disclosure SEC source: 0001209191-20-045701 · doc4.xml · nonDerivative · entry 3 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 790,193 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 17, 2020. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.20 to $72.10 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 06, 2020 Filed Aug 7, 2020 17:42 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	42,337	$70.76	$2,995,969.34	Disclosure SEC source: 0001209191-20-045701 · doc4.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 801,455 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 17, 2020. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.215 to $71.195 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
June 04, 2020 Filed Jun 8, 2020 23:23 UTC	EXICURE, INC. XCUR · Entity 8068	GrantStock Option (right to buy) · Derivative	21,693	$0.00 Strike: $2.79	$0.00	Disclosure SEC source: 0001209191-20-035127 · doc4.xml · derivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,693 Underlying: Common Stock · 21,693 shares Expires 2030-06-03 F1 · derivative.exercise_date: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of June 4, 2020, provided the Reporting Person remains in continuous service on each vesting date. Read SEC document
May 21, 2020 Filed Aug 7, 2020 17:42 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GiftOrdinary Shares	5,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-045701 · doc4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 843,792 F1 · balance_after: Includes 1,049 ordinary shares of the Issuer acquired on June 1, 2020 pursuant to an employee stock purchase program. Read SEC document
May 20, 2020 Filed May 21, 2020 20:32 UTC	Zyla Life Sciences ZCOR · Entity 148990	Disposition to issuerCommon Stock	26,953	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-20-064795 · a4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time. F2 · kind: Includes unvested time-based restricted stock units representing a contingent right to receive 26, 953 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit. F1 · price: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time. F2 · price: Includes unvested time-based restricted stock units representing a contingent right to receive 26, 953 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit. Read SEC document
May 20, 2020 Filed May 23, 2020 00:57 UTC	Assertio Holdings, Inc. ASRT · Entity 37706	GrantCommon Stock	211,111	$0.00	$0.00	Disclosure SEC source: 0001104659-20-065548 · a4.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,111 F4 · shares: One-third of these restricted stock units are scheduled to vest on each of May 20, 2021, 2022 and 2023, assuming continued service through the applicable vesting date. Read SEC document
May 20, 2020 Filed May 23, 2020 00:57 UTC	Assertio Holdings, Inc. ASRT · Entity 37706	GrantCommon Stock	49,143	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-20-065548 · a4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,143 F1 · kind: Common stock of Assertio Holdings, Inc. ("Issuer") acquired at the effective time ("Effective Time") of the transactions contemplated in the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Zyla Life Sciences ("Zyla") and the other parties thereto. Pursuant to the Merger Agreement, each share of Zyla common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive, and became exchangeable for 2.5 shares of Issuer common stock. Issuer common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time. F2 · kind: Additionally, all outstanding time-based restricted stock units of Zyla were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Issuer common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Zyla common stock covered by such restricted stock unit. F3 · shares: Totals exclude shares withheld by the Issuer for applicable tax withholdings. F1 · price: Common stock of Assertio Holdings, Inc. ("Issuer") acquired at the effective time ("Effective Time") of the transactions contemplated in the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Zyla Life Sciences ("Zyla") and the other parties thereto. Pursuant to the Merger Agreement, each share of Zyla common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive, and became exchangeable for 2.5 shares of Issuer common stock. Issuer common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time. F2 · price: Additionally, all outstanding time-based restricted stock units of Zyla were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Issuer common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Zyla common stock covered by such restricted stock unit. Read SEC document
April 23, 2020 Filed Apr 24, 2020 22:13 UTC	Zyla Life Sciences ZCOR · Entity 148990	Exercise / conversionRestricted Stock Units · Derivative	6,667	$0.00	$0.00	Disclosure SEC source: 0001179110-20-005107 · edgar.xml · derivative · entry 3 Walbert Timothy P · CIK 0001349376 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Stock · 6,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Stock Units convert into Common Stock on a one-for-one basis. F3 · derivative.exercise_date: On April 23, 2019 the reporting person was granted 20,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date. F3 · derivative.expiration_date: On April 23, 2019 the reporting person was granted 20,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date. Read SEC document
April 23, 2020 Filed Apr 24, 2020 22:13 UTC	Zyla Life Sciences ZCOR · Entity 148990	Tax withholdingCommon Stock	952	$1.75	$1,666.00	Disclosure SEC source: 0001179110-20-005107 · edgar.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,715 F1 · shares: Represents shares withheld to pay taxes applicable to vesting of restricted stock units. Read SEC document
April 23, 2020 Filed Apr 24, 2020 22:13 UTC	Zyla Life Sciences ZCOR · Entity 148990	Exercise / conversionCommon Stock	6,667	$1.75	$11,667.25	Disclosure SEC source: 0001179110-20-005107 · edgar.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On April 23, 2019 the reporting person was granted 20,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date. Read SEC document
April 23, 2020 Filed Apr 28, 2020 23:40 UTC Amendment	Zyla Life Sciences ZCOR · Entity 148990	Exercise / conversionRestricted Stock Units · Derivative	6,667	$0.00	$0.00	Disclosure SEC source: 0001179110-20-005217 · edgar.xml · derivative · entry 3 Walbert Timothy P · CIK 0001349376 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Stock · 6,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Stock Units convert into Common Stock on a one-for-one basis. F3 · derivative.exercise_date: On April 23, 2019 the reporting person was granted 20,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date. F3 · derivative.expiration_date: On April 23, 2019 the reporting person was granted 20,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date. Read SEC document
April 23, 2020 Filed Apr 28, 2020 23:40 UTC Amendment	Zyla Life Sciences ZCOR · Entity 148990	Tax withholdingCommon Stock	1,805	$1.75	$3,158.75	Disclosure SEC source: 0001179110-20-005217 · edgar.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,862 F1 · shares: Represents shares withheld to pay taxes applicable to vesting of restricted stock units. Read SEC document
April 23, 2020 Filed Apr 28, 2020 23:40 UTC Amendment	Zyla Life Sciences ZCOR · Entity 148990	Exercise / conversionCommon Stock	6,667	$1.75	$11,667.25	Disclosure SEC source: 0001179110-20-005217 · edgar.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On April 23, 2019 the reporting person was granted 20,000 time-based restricted stock units that were eligible to vest 1/3 on each of the first three anniversaries of the grant date. Read SEC document
March 04, 2020 Filed Mar 6, 2020 01:44 UTC	Zyla Life Sciences ZCOR · Entity 148990	GrantCommon Stock	13,620	$0.00	$0.00	Disclosure SEC source: 0001179110-20-003204 · edgar.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,620 F1 · shares: Represents restricted stock units, which vest the day prior to the Company's annual meeting of stockholders to be held in 2021. Read SEC document
February 21, 2020 Filed Feb 21, 2020 20:07 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	93,864	$35.23	$3,306,828.72	Disclosure SEC source: 0001209191-20-011830 · doc4.xml · nonDerivative · entry 3 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847,743 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the reporting person on May 23, 2019. Read SEC document
February 19, 2020 Filed Feb 21, 2020 20:07 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantPerformance Restricted Stock Units (PSUs) · Derivative	96,864	$0.00	$0.00	Disclosure SEC source: 0001209191-20-011830 · doc4.xml · derivative · entry 5 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,864 Underlying: Ordinary Shares · 96,864 shares Expires not disclosed F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F1 · kind: On January 5, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 19, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2021 and January 5, 2022. F1 · derivative.exercise_date: On January 5, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 19, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2021 and January 5, 2022. F1 · derivative.expiration_date: On January 5, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 19, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2021 and January 5, 2022. Read SEC document
February 19, 2020 Filed Feb 21, 2020 20:07 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Tax withholdingOrdinary Shares	21,457	$36.06	$773,739.42	Disclosure SEC source: 0001209191-20-011830 · doc4.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 941,607 Read SEC document
February 19, 2020 Filed Feb 21, 2020 20:07 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantOrdinary Shares	48,432	$0.00	$0.00	Disclosure SEC source: 0001209191-20-011830 · doc4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 963,064 F1 · kind: On January 5, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 19, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2021 and January 5, 2022. Read SEC document
February 01, 2020 Filed Feb 4, 2020 16:14 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units (RSUs) · Derivative	9,086	$0.00	$0.00	Disclosure SEC source: 0001209191-20-006292 · doc4.xml · derivative · entry 4 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 18,174 Underlying: Ordinary Shares · 9,086 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The RSUs vest 1/3 annually on each anniversary of February 1, 2019 (the grant date). F2 · derivative.expiration_date: The RSUs vest 1/3 annually on each anniversary of February 1, 2019 (the grant date). Read SEC document
February 01, 2020 Filed Feb 4, 2020 16:14 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Tax withholdingOrdinary Shares	2,668	$34.49	$92,019.32	Disclosure SEC source: 0001209191-20-006292 · doc4.xml · nonDerivative · entry 2 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 9,150 Read SEC document
February 01, 2020 Filed Feb 4, 2020 16:14 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionOrdinary Shares	9,086	$0.00	$0.00	Disclosure SEC source: 0001209191-20-006292 · doc4.xml · nonDerivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 11,818 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 21, 2020 Filed Jan 23, 2020 16:25 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantPerformance Restricted Stock Units (PSUs) · Derivative	2,575	$0.00	$0.00	Disclosure SEC source: 0001209191-20-004677 · doc4.xml · derivative · entry 6 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 2,575 Underlying: Ordinary Shares · 2,575 shares Expires not disclosed F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F2 · kind: On March 1, 2019, the Reporting Person's spouse was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest on January 21, 2021. F2 · derivative.exercise_date: On March 1, 2019, the Reporting Person's spouse was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest on January 21, 2021. F2 · derivative.expiration_date: On March 1, 2019, the Reporting Person's spouse was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest on January 21, 2021. Read SEC document
January 21, 2020 Filed Jan 23, 2020 16:25 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantPerformance Restricted Stock Units (PSUs) · Derivative	40,666	$0.00	$0.00	Disclosure SEC source: 0001209191-20-004677 · doc4.xml · derivative · entry 5 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,666 Underlying: Ordinary Shares · 40,666 shares Expires not disclosed F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F1 · kind: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. F1 · derivative.exercise_date: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. F1 · derivative.expiration_date: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. Read SEC document
January 21, 2020 Filed Jan 23, 2020 16:25 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Tax withholdingOrdinary Shares	891	$38.25	$34,080.75	Disclosure SEC source: 0001209191-20-004677 · doc4.xml · nonDerivative · entry 4 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 2,732 Read SEC document
January 21, 2020 Filed Jan 23, 2020 16:25 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantOrdinary Shares	2,574	$0.00	$0.00	Disclosure SEC source: 0001209191-20-004677 · doc4.xml · nonDerivative · entry 3 Walbert Timothy P · CIK 0001349376 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 3,623 F2 · kind: On March 1, 2019, the Reporting Person's spouse was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest on January 21, 2021. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.